Heska (HSKA) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HSKA shares.
View HSKA analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1-year target prices for Heska's shares. Their HSKA share price forecasts range from $120.00 to $150.00. On average, they anticipate the company's share price to reach $137.25 in the next twelve months. This suggests a possible upside of 14.4% from the stock's current price.
View analysts price targets for HSKA or view top-rated stocks among Wall Street analysts.

Heska Co. (NASDAQ:HSKA) posted its earnings results on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.23. The medical research company earned $60.24 million during the quarter, compared to the consensus estimate of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.94% and a negative net margin of 7.86%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.25) earnings per share.

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Heska's stock is owned by a number of institutional and retail investors. Top institutional investors include Everence Capital Management Inc. (0.02%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends.

One share of HSKA stock can currently be purchased for approximately $119.99.

Heska (NASDAQ:HSKA) has a market capitalization of $1.31 billion and generates $257.31 million in revenue each year. The medical research company earns $-19,890,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

The company employs 808 workers across the globe.

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.